Moderna (MRNA) Inventory Average (2021 - 2026)

Moderna (MRNA) has 6 years of Inventory Average data on file, last reported at $149.5 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $149.5 million, up 22.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.5 million (up 22.04% YoY), and the FY2025 annual result was $135.0 million, down 15.36% from the prior year.
• Inventory Average eased to $149.5 million in Q1 2026 per MRNA's latest filing, from $242.5 million in the prior quarter.
• Over five years, Inventory Average peaked at $2.0 billion in Q3 2022 and troughed at $122.5 million in Q1 2025.
• A 5-year average of $699.7 million and a median of $347.0 million in 2024 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2022 and 2023: Inventory Average soared 525.32% in 2022, then tumbled 77.23% in 2023.
• A 5-year view of Inventory Average shows it stood at $1.5 billion in 2022, then plunged by 77.23% to $344.5 million in 2023, then fell by 23.22% to $264.5 million in 2024, then retreated by 8.32% to $242.5 million in 2025, then sank by 38.35% to $149.5 million in 2026.
• Business Quant data shows MRNA's Inventory Average at $149.5 million in Q1 2026, $242.5 million in Q4 2025, and $286.0 million in Q3 2025.